קסנזין 25 מ"ג - Xenazine 25 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | N07XX Other nervous system drugs | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||||||||
| צ×רת ××ª× | פ××× - PER OS | ||||||||||||||||||||||||
| צ×רת ××× ×× | ×××××, TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||||||||
| ×ת×××× | Movement disorders, associated with organic central nervous system conditions, e.g. Huntington's chorea, hemiballismus and senile chorea.Moderate to severe tardive dyskinesia, which is disabling and/or socially embanassing. The condition should be persistent despite a switch to atypical antipsychotic medication and/or reduction in dosage of antipsychotic medication, when withdrawal of antipsychotic medication is not a realistic option.
| ||||||||||||||||||||||||
| |||||||||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×§×¡× ××× 25 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | RECIPHARM FONTAINE, FRANCE |
| ×©× ××¢× ×ר×ש×× | NEOPHARM LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 04/2011. ר×ש××× ×ת×ר××: 11/2014 |
| ת×ר×× ×¢×××× ××ר×× | 15/05/19 |
השינוי האחרון נעשה בֹ־21 באוגוסט 2022 ב־08:06